To our knowledge, this phase 2 trial represents the first prospective investigation into the use of a PD-1-blocking antibody combined with immunochemotherapy MTR regimen for previously untreated PCNSL patients. This evidence concerns the gene PDCD1 and primary central nervous system lymphoma.